Antibiotic Drug Resistance in HIV Seropositive Pregnant Women

Kwashie Ajibade Ako-Nai^1, and Omo-Omorodion B. I.¹

¹Department of Microbiology, Obafemi Awolowo University, Ile-Ife, Nigeria

Cite this paper:
Kwashie Ajibade Ako-Nai and Omo-Omorodion B. I.. Antibiotic Drug Resistance in HIV Seropositive Pregnant Women. American Journal of Microbiological Research. 2019; 7(2):45-50. doi: 10.12691/ajmr-7-2-2

Abstract

Background: Vaginal infections are often associated with a significant risk of morbidity especially in pregnant women. These infections if left untreated often result in a long-term sequelae and poses a higher adverse pregnancy outcome especially in immunocompromised women. While HIV infection has been reported to be a high risk of pathogenic bacterial colonization, the misuse of antibiotics is high among women in developing countries. Methodology and results: A high vaginal swab was collected from the posterior fornix from each pregnant women by the attending physician using sterile bivalve speculum and a cotton- tipped applicator. Each sample was cultured and identified using standard bacterlogical methods. Selected pathogens were thereafter tested for their sensitivity to 23 commonly prescribed antibiotics using the Kirby-Bauer method. Altogether, 1,156 bacterial isolates were cultured from high vaginal swabs of both 114 HIV seropositive and 126 HIV seronegative pregnant women, averaging 4.81 bacterial per subject each for both cohorts. S. aureus was seen as the single predominant isolate recovered from both groups. In addition, of the 22 S. aureus recovered from HIV infected women, 10 isolates were Methicillin resistant S. aureus (MRSA) and 12 Methicillin sensitive S aureus (MSSA), while, of the 25 S. aureus recovered from HIV seronegative women, 13 isolates were Methicillin resistant S. aureus (MRSA) and 12 Methicillin sensitive S aureus (MSSA). Other gram negative pathogens associated with lower genital infections were also studied. Conclusion: The incidence of multiple antibiotic resistance was high among isolates recovered from both cohorts, which is probably due to uncontrollable ease of access to these antibiotics in the environment where antibiotics restriction/policy is lacking. There is an urgent need for continuous monitoring, health education, drug abuse awareness and implementation of interventions to restrict antibiotic abuse especially among immunocompromised individuals in the study environment.

Keywords:
bacterial isolates antibiotics resistance high vaginal swab HIV pregnant women

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Klouman E., Masenga E. J., Klepp K-I et al. HIV and reproductive tract infections in a total village population in rural Kilimanjaro, Tanzania: women at increased risk. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14:163-168.
[2]	Sewankambo N., Gray R. H., Wawer M. J. et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet, 1997, 350:546-550.
[3]	French R., Brocklehurst P. The effect of pregnancy on survival in women infected with HIV a systematic review of literature and meta-analysis. British journal of Obstetrics and Gynaecology, 1998, 105: 827-835.
[4]	Leroy V., De Clerq A, Ladner J. et al. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? Genitourin Med, 1995, 71(4): 207-211.
[5]	John G. C., Nduati R. W., Mbori-Ngacha D. et al. Genital shedding of human immunodeficiency virus type-1 DNA during pregnancy: association with immunosuppression, abnormal cervical and vaginal discharge and severe vitamin A deficiency. J Infect Dis, 1997, 175(1): 57-62.
[6]	Brocklehurst P., French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. British Journal of Obstetrics and Gynaecology, 1998, 105: 839-848.
[7]	Brenchley J. M., Douek D. C. Microbial translocation across the GI tract. Annu Rev Immunol 2012; 30: 149-73.
[8]	Iroha I., Nwakeze E., Ejikeugwu C., Oji A., Udu-Ibiam E., et al. Frequency and antibiogram of uropathogens isolated from urine samples of HIV infected patients on ART. Am J Biosc 2013; 1:50-53.
[9]	Adegoke A. A., Tom Mvuyo, Okoh A., Steve J. Studies on multiple antibiotic resistant bacteria isolated from surgical site infections. Scientific Research and Essays 2010; 5: 3876-3881.
[10]	Mesaros N., Nordmann P., Plésiat P., Roussel-Delvallez M., Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: Resistance and therapeutic options at the turn of the new millenium. Clin Microbiol Infect. 2007; 13: 560-78.
[11]	Olanike O. K. and Babatunde E. O. The Pattern of Antibiotic use in an Urban Slum in Lagos State, Nigeria. West African Journal of Pharmacy, 2013, 24(1) 49-57. 12 .
[12]	Philip P. J., John T., Sigrid K., Brandi L., Lowery H. K.. Resistant Staphylococcus aureuscolonization of the groin and risk of clinical infection among HIV infected adults. Emerging Infectious Diseases 2013; 19: 4.
[13]	Hidron A. I., Kempker R., Moanna A., Rimland D. Methicillin-resistant Staphylococcus aureus in HIV-infected patients. Infect Drug Resist 2010; 3: 73-86.
[14]	Ako-Nai K. A., Adeyemi F. M.., Adejuyigbe E., Ebhodaghe B. I., Osho P. O., Oyeniyi T. T., Kassim O. O. The Dynamics of Bacteria Population on the Skin, Throat and Gastrointestinal tract of HIV Seropositive Patients. Annals of Tropical Medicine and Public health 2015; 8(5):164-176.
[15]	Magiorakos A. P., Srinivasan A., Carey R. B., Carmeli Y., Falagas M. E. Multidrug resistant, extensively drug-resistant and Pan drug resistant bacteria: An International expert proposal for interim standard definitions for acquired resistance. ClinMicrobiol Infect 2012; 18: 268-281.
[16]	Frank-Peterside N., Chukwugozim R., Okerentugha P. O. HIV-1-2 co-infection with multidrug resistant (MDR) uropathogens in Portharcourt, Nigeria. Nature and Science 2013; 11: 11- 20.
[17]	Livermore D.M. Penicillin-binding proteins, porins and outer-membrane permeability of carbenicillin-resistant and -susceptible strains of Pseudomonas aeruginosa. J Med Microbiol 1984; 18: 261-70.
[18]	Ako-Nai K. A., Makun C. I., Omo-Omorodion B. I. Resistant Bacterial agents in HIV-seropositive Pregnant Women. World Journal on Pharmaceutical Research 2019; 8(2): 167-179.
[19]	Adeyemi F. M., Akonai K. A., Oyemiyi T. T., Kassim O. O., Blessing I. E., et al. (2015) Molecular characterization and antibiotic resistance profiles of bacterial isolates cultured from HIV seropositive patients. Archives of Clinical Microbiology 6: 1-12.
[20]	Ebhodaghe, B. I., Ako-Nai K. A. and Aderoba A. K. Evaluation of risk factors in MTCT among HIV-seropositive pregnant women in selected centres in Akure, South western Nigeria. Annals of tropical medicine and public health 2017; 10(1): 165-181.
[21]	M. F. Cotton, E. Wasserman, J. Smit, A. Whitelaw, and H. J. Zar, “High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa,” BMC Infectious Diseases, vol. 8,article 40, 2008.
[22]	Murugesh K., Deepa S., Venkatesha D. Multi drug resistant uropathogens in HIV: Are they a threat to community. Int J Scientific Study 2014; 2: 38-42.
[23]	Adeyemi A. I., Sulaiman A. A., Solomon B. B., Chinedu O. A., Victor I. A. Bacterial Bloodstream Infections in HIV-infected adults attending a Lagos teaching hospital. J Health Popul Nutr 2010; 28: 318-26.
[24]	Abujnah A. A., Zorgani A., Sabri M. A., El-Mohammady H., Khalek R. A., Ghenghesh K. S. Multidrug resistance and extendedspectrum b-lactamases genes among Escherichia coli from patients with urinary tract infections in Northwestern Libya. Libyan J Med 2015; 2(10): 26412.
[25]	Tomás M., Doumith M., Warner M., Turton J. F., Beceiro A., Bou G., et al. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2010; 54: 2219-24.
[26]	Joly-Guillou M. L., Kempf M., Cavallo J. D., Chomarat M., Dubreuil L., Maugein J., et al. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010; 10: 72.